Viking Upsizes Offering to $500M, Prices Shares at $35
VKTX sits 52% above its 52-week low of $24.78 on elevated volume (5.2× avg).
Summary
Viking Therapeutics priced its upsized concurrent offering at $500 million, up from the previously announced $400 million. The deal includes 7.86 million common shares at $35.00 each and $250 million in convertible senior notes. The pricing represents a discount to the last close of $37.55, reflecting dilution pressure. This follows positive Phase 2 maintenance data for VK2735 announced two days ago, which likely drove demand for the raise. The company is capitalizing on the stock's strength to fund its obesity pipeline.
At the time of this announcement, VKTX was trading at $37.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $24.78 to $43.15. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.